0000000000223427

AUTHOR

Elodia Claudia Martino

showing 6 related works from this author

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX ch…

2013

The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400…

OncologyMaleCancer ResearchGranulocyte-macrophage-colonystimulating- factorOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinColorectal NeoplasmGastroenterologyDeoxycytidineFOLFOXAldesleukinPhase iii trialAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineChemoimmunotherapyNeoplasm MetastasisAged 80 and overAldesleukinMiddle AgedNeoplasm MetastasiOxaliplatinColorectal carcinomaTreatment OutcomeFluorouracilFemaleFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultmedicine.medical_specialtyImmunologyLymphocytes Tumor-InfiltratingChemoimmunotherapyInternal medicineHumansAgedPharmacologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundGranulocyte-Macrophage Colony-Stimulating FactorGemcitabineGemcitabineOxaliplatinRegimenInterleukin-2Neoplasm GradingbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

2015

Thymidylate synthase (TS) poly-epitope peptide (TSPP) is a 27-mer peptide vaccine containing the amino acidic sequences of three epitopes with HLA-A2.1-binding motifs of TS, an enzyme overexpressed in cancer cells, which plays a crucial role in DNA repair and replication. Based on the results of preclinical studies, we designed a phase Ib trial (TSPP/VAC1) to investigate, in a dose escalation setting, the safety and the biological activity of TSPP vaccination alone (arm A) or in combination with GM-CSF and IL-2 (arm B) in cancer patients. Twenty-one pretreated metastatic cancer patients, with a good performance status (ECOG ≤ 1) and no severe organ failure or immunological disease, were enr…

MaleCancer Researchmedicine.medical_treatmentImmunologyPharmacologyThymidylate synthaseCancer VaccinesCTLsNeoplasmsCancer vaccineMedicineImmunology and AllergyHumansImmune responseAdverse effectAgedbiologyPerformance statusbusiness.industryPhase Ib trialCancerImmunotherapyThymidylate SynthaseMiddle Agedmedicine.diseaseCancer vaccine; CTLs; Immune response; Immunotherapy; Phase Ib trial; Cancer Research; Oncology; Immunology; Immunology and AllergyOncologyCTLImmunologyToxicityVaccines Subunitbiology.proteinPeptide vaccineFemaleCancer vaccineImmunotherapybusinessCancer immunology, immunotherapy : CII
researchProduct

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

2016

AbstractThe mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In previous studies, this regimen showed powerful anti-angiogenetic effects and significant antitumor activity in metastatic non-small-cell lung cancer (mNSCLC) patients. We also recorded the best benefit in patients exhibiting low-systemic inflammatory profile at baseline. On these bases, we hypothesized that mPEBev antitumor activity could be partially related to bevacizumab-associated immunological effects. For this reason, we performed an immunological monitoring in 59 out …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabmedicine.medical_treatmentImmunologybevacizumabArticleProinflammatory cytokine03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineIn vivoInternal medicinemedicinebevacizumab lung cancer immunocytofluorimetric analysisLung cancerCisplatinChemotherapybusiness.industryCell Biologymedicine.diseaselung cancerRegimenCTL*030104 developmental biology030220 oncology & carcinogenesisImmunologyimmunocytofluorimetric analysisbevacizumab non small lung cancer immune system vegf t lymphocytesbusinessmedicine.drugCell Death Discovery
researchProduct

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy aft…

2016

Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations. Twenty-two patients with resectable prostate cancer, with a mean age of 67 (+/−3.93) years, who receiv…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorChemokyne Receptor 7Prostate cancer0302 clinical medicineRecurrencePD-1Tumor MicroenvironmentForkhead Transcription Factorshemic and immune systemsprostate cancerPrimary tumorChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytesOncologytumor infiltrating lymphocytes030220 oncology & carcinogenesisMolecular MedicineprognosiResearch PaperReceptors CCR7medicine.medical_specialtydisease-free survivaloverall survivalchemical and pharmacologic phenomena03 medical and health sciencesLymphocytes Tumor-InfiltratingMedian follow-upFoxP3Internal medicineChemokyne Receptor 7; disease-free survival; FoxP3; overall survival; PD-1; prognosis; prostate cancer; radiotherapy; T regulators lymphocytes; tumor infiltrating lymphocytes; Molecular Medicine; Oncology; Pharmacology; Cancer ResearchT regulators lymphocytesmedicineHumansProgression-free survivalRadical surgeryradiotherapyAgedSalvage TherapyPharmacologybusiness.industryTumor-infiltrating lymphocytesProstatic Neoplasmsmedicine.diseaseRadiation therapyT regulators lymphocyte030104 developmental biologyTumor progressionprognosistumor infiltrating lymphocytebusinessCancer Biology & Therapy
researchProduct

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

2016

Even though the crucial role played by inflammation in cancer development and progression was first hypothesized by Rudolf Virchow at the beginning of the nineteenth century, only recently inflammation has been recognized as a hallmark of cancer. At present, the biology underlying the humoral and cellular immune-suppressive cancer-associated inflammatory microenvironment is an active area of preclinical and clinical investigation.1, 2 Indeed, the possibility to modulate the inflammatory/immune microenvironment, by either antagonizing the tumor-associated immune-suppression or by enhancing the pre-existing anti-cancer immune response in tumor tissues, is a promising therapeutic option for ca…

0301 basic medicineCancer ResearchBevacizumabAngiogenesisColorectal cancerImmunologyInflammationModels Biologicalimmune responseProinflammatory cytokineImmunomodulation03 medical and health sciencesCellular and Molecular Neuroscienceinflammation angiogenesis and anti-cancer immune response0302 clinical medicineImmune systemNeoplasmsmedicinecancerCytotoxic T cellAnimalsHumansangiogenesis and anti-cancer immune responseNeovascularization Pathologicbusiness.industryangiogenesiFOXP3Cell BiologyNews and Commentarymedicine.diseaseBevacizumab030104 developmental biologyinflammation030220 oncology & carcinogenesisImmunologymedicine.symptombusinessmedicine.drug
researchProduct

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorect…

2015

ABSTRACT: Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5′-fluorouracil (5′-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1–2], bolus/infusi…

0301 basic medicinemedicine.medical_specialtyepitope peptidesImmunologyGOLFIG chemo-immunotherapythymidylate synthaseGastroenterologyThymidylate synthaseCTLs03 medical and health sciences0302 clinical medicineBolus (medicine)SargramostimInternal medicinepeptide vaccineMedicineImmunology and AllergyOriginal Researchbiologybusiness.industryColon cancer; CTLs; epitope peptides; GOLFIG chemo-immunotherapy; peptide vaccine; thymidylate synthase; Immunology and Allergy; Oncology; ImmunologyGemcitabineOxaliplatinColon cancerRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisConcomitantImmunologyCTLbiology.proteinbusinessepitope peptidemedicine.drug
researchProduct